Toxicity

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

Retrieved on: 
пятница, мая 31, 2024
Toxicity, FDA, Male, OLP, Safety, LIPO, Tacrolimus, SIV, Institutional review board, Pain, Lichen planus, IRB, Female, Pharmaceutical industry

PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating LP-310 in the treatment of Oral Lichen Planus (OLP). With clearance received from the central Institutional Review Board (IRB), the Phase 2a trial is set to commence with site qualifications completed and patient recruitment underway.

Key Points: 
  • Patient recruitment is underway for Phase 2a multicenter, dose-ranging study
    PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating LP-310 in the treatment of Oral Lichen Planus (OLP).
  • With clearance received from the central Institutional Review Board (IRB), the Phase 2a trial is set to commence with site qualifications completed and patient recruitment underway.
  • Lipella’s Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects experiencing symptomatic OLP.
  • Dr. Jonathan Kaufman, CEO of Lipella, expressed his enthusiasm, stating, “We are extremely pleased to announce the completion of the Site Initiation Visit for our Phase 2a trial of LP-310.

Azitra, Inc. Announces Presentation at the 2024 BIO International Convention

Retrieved on: 
пятница, мая 31, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Health, Netherton, Netherton syndrome, EGFR, San Diego Convention Center, Toxicity, BIO

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.

Key Points: 
  • Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.
  • The presentation will take place on Wednesday, June 5, 2024 at 12:00 PM PDT in Theater 3 at the San Diego Convention Center.
  • The corporate update will highlight Azitra’s updates and progress on its pipeline, including ATR-12 in development for Netherton syndrome and ATR-04 in development for epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity.
  • Azitra’s presentation details are as follows:
    To schedule a meeting with the Company’s management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact [email protected]

Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO

Retrieved on: 
пятница, мая 31, 2024
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Patient, TC, Toxicity, Texas Oncology, Diagnosis, Triple-negative breast cancer, Breast cancer, Gene expression, FLEX, HR, MD, Neoplasm, Taxane, ASCO, Cyclophosphamide, Woman, Breast Cancer Research, Society, Baylor University Medical Center, Quality of life, Medical imaging

Agendia®, Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens at the 2024 Annual American Society of Clinical Oncology (ASCO) Meeting , taking place in Chicago, IL.

Key Points: 
  • Agendia®, Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens at the 2024 Annual American Society of Clinical Oncology (ASCO) Meeting , taking place in Chicago, IL.
  • The FLEX study investigates the 3-year outcome of patients with HR+HER2-, genomically High Risk Luminal B-Type early breast cancer, who have undergone treatment consisting of chemotherapy with taxane and cyclophosphamide (TC) or chemotherapy with anthracycline + TC (AC-T).
  • "The ability to tailor treatment regimens to a patient’s tumor biology is crucial to optimize outcomes and quality of life.
  • MammaPrint's utility in guiding treatment planning is highlighted by these new data evaluating chemotherapy selection," said Dr. O'Shaughnessy.

Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology

Retrieved on: 
среда, мая 29, 2024
Patient, Infection, Mesothelioma, Neuroblastoma, Measles, Human, Toxicity, Science, HPV, RNA, Clinical trial, Fruit, Vaccine, Research, Potyvirus, Pasteur Institute, Virus, GMP

Paris, 29 May 2024 - Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed to design and develop vaccine candidates through to proof of concept in humans.

Key Points: 
  • Paris, 29 May 2024 - Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the joint Institut Pasteur - Oncovita laboratory is aimed to design and develop vaccine candidates through to proof of concept in humans.
  • Oncovita and the Institut Pasteur have already been working together for several years on the construction and development of new vaccines based on MeasovirR technology, based on the measles vaccine virus.
  • The production method in accordance with good manufacturing practice (GMP) is under development in order to initiate   the first clinical trial.
  • The joint Institut Pasteur - Oncovita laboratory will also be carrying out research into viral defective interfering RNAs (DI-RNAs) produced by modified recombinant measles viruses.

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

Retrieved on: 
среда, мая 29, 2024
Research, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, EBV, Patient, Cell, Epstein–Barr virus, Phenotype, ISCT, Toxicity, SLE, Cytokine, CD19, International Society, ATRA, Cancer, Autoimmunity, PDT, IL-6, NHL, Inflammation, Lupus nephritis, Annual general meeting, Vaccine

Findings demonstrate that ATA3219 maintains comparable cytotoxic function and potency while inducing lower levels of pro-inflammatory cytokines compared to autologous benchmark CD19 CAR T cells.

Key Points: 
  • Findings demonstrate that ATA3219 maintains comparable cytotoxic function and potency while inducing lower levels of pro-inflammatory cytokines compared to autologous benchmark CD19 CAR T cells.
  • The data will be presented in a poster session at the International Society for Cell & Gene Therapy (ISCT) 2024 Annual Meeting taking place May 29 to June 1, 2024, in Vancouver, Canada.
  • ATA3219 consists of allogeneic CD19-directed CAR EBV T cells that have been optimized to offer a potential best-in-class profile and off-the-shelf availability.
  • “We are pleased to share promising preclinical data that shows ATA3219 mediates robust B-cell depletion against SLE and multiple sclerosis patient derived immune cells.

Veristat Appoints Gabriela Rosu, M.D., to Lead Growing Medical Affairs Team

Retrieved on: 
среда, мая 29, 2024
Research, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, FDA, Health, ChromeOS, Toxicity, Safety, MD, ASCO, Abstract, Communication, Society, ESMO, Multimedia, Annual general meeting, Nursing

Veristat, the Science-First Full Service CRO and Consultancy, is pleased to announce that Gabriela Rosu, M.D., has joined as Senior Director, Global Medical Affairs.

Key Points: 
  • Veristat, the Science-First Full Service CRO and Consultancy, is pleased to announce that Gabriela Rosu, M.D., has joined as Senior Director, Global Medical Affairs.
  • Veristat’s Medical Affairs team is at the forefront of evaluating scientific data to address the increasing complexity of biotherapeutic compounds and diverse patient demographics in clinical trials.
  • In her new role, Dr. Rosu will oversee the global expansion of the medical and safety/pharmacovigilance teams.
  • Reflecting on her new position, Dr. Rosu stated, "I am honored to lead as Senior Director, Global Medical Affairs at Veristat, aligning with the company’s strategic vision to pioneer the development and commercialization of innovative treatments for rare diseases.

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

Retrieved on: 
среда, мая 29, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, GBM, Decompression (diving), Patient, Survival, VBI, Vaccine, Toxicity, Doctor of Philosophy, Disease, Poster, ASCO, PR, Society, DCR, Combination therapy, Annual general meeting, Pharmaceutical industry

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s immunotherapeutic cancer vaccine candidate, in recurrent glioblastoma (rGBM) patients.
  • These data will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 1, 2024.
  • The approved treatments for recurrent GBM patients have limited to no efficacy, which is consistent with the data seen in the standard-of-care arm in this study.
  • Throughout the remainder of 2024, we expect to have additional tumor response data and initial survival data.

A2 Bio Highlights Progress of CAR T-Cell Clinical Programs in Three Poster Presentations during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Retrieved on: 
среда, мая 29, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, HLA, Patient, Toxicity, Mayo Clinic, Clinical trial, Allele, FIH, LOH, Safety, Leukapheresis, Carcinoembryonic antigen, ASCO, Medicine, Society, MSLN, CEA, Annual general meeting, Pharmaceutical industry

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, will present updates on three ongoing clinical trials in poster presentations during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, will present updates on three ongoing clinical trials in poster presentations during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • “Diversity in clinical studies is essential to address racial and ethnic groups who are often underrepresented in clinical trials, especially in precision medicine studies using genetic data.
  • We are creating the future of precision medicine by applying advanced bioinformatics in our BASECAMP-1 prescreening protocol to efficiently screen patients for enrollment in these ongoing CAR T-cell clinical trials.
  • For more information on A2 Bio clinical trials, please visit https://www.a2bioclinicaltrials.com/

$22.46 Billion Biopesticides and Biofertilizers Markets - A Global and Regional Analysis, 2023-2033: Opportunities in the Adoption of Nano-Biopesticides and Cutting-Edge Genetic Engineering Technology - ResearchAndMarkets.com

Retrieved on: 
среда, мая 29, 2024
General Health, Environmental Health, Agriculture, Natural Resources, Environment, Genetics, Organic Food, Retail, Chemicals, Plastics, Biotechnology, Manufacturing, Health, Texas A&M AgriLife, Fertility, Nitrogen, Toxicity, Risk, Biopesticide, Soil, Food security, Farmer, Ecosystem, Private limited company, Bacteria, Novozymes, Food, Fertilizer, Absorption, IPM, Name, Growth, Research, GSFC, Fungus, Nutrient, UPL, Bacillus thuringiensis, Seemabaddha, Virus, Hand, Plant, Enzyme

The "Global Biopesticides and Biofertilizers Market: A Global and Regional Analysis, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biopesticides and Biofertilizers Market: A Global and Regional Analysis, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • North America led the global biopesticides and biofertilizers market in 2022 owing to a combination of factors that underscore the region's commitment to sustainable agriculture.
  • The market study on the biopesticides and biofertilizers market considered biopesticides to be naturally derived substances or microorganisms used for controlling pests, diseases, or weeds in agriculture.
  • The convenience of application through irrigation systems further contributes to the appeal of liquid forms in the biopesticides and biofertilizers market.

ExpressionEdits Raises $13M in Seed Funding to Advance Protein Expression Using AI-Driven Intronization Technology

Retrieved on: 
среда, мая 29, 2024
Other Science, Pharmaceutical, Research, Artificial Intelligence, Oncology, Software, Infectious Diseases, Genetics, Data Management, Stem Cells, Science, Technology, Clinical Trials, Cardiology, FDA, Biotechnology, Agriculture, Natural Resources, Health, Intron, DNA, University, Gene expression, Toxicity, Machine learning, Algorithm, AI, Growth, Octopus Group, Genome, Tissue, Gene, A-DNA, Therapy, Multimedia, Vaccine

ExpressionEdits , a biotechnology company optimizing protein expression using AI and proprietary intronization technology, announced today a $13 million seed funding round co-led by Octopus Ventures and redalpine, with participation from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail.

Key Points: 
  • ExpressionEdits , a biotechnology company optimizing protein expression using AI and proprietary intronization technology, announced today a $13 million seed funding round co-led by Octopus Ventures and redalpine, with participation from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail.
  • By strategically incorporating multiple short noncoding DNA sequences known as introns into artificial genes, ExpressionEdits has achieved significant enhancements in gene expression which leads to better protein production.
  • “At ExpressionEdits, we're revolutionizing gene expression by putting introns back where they belong, resulting in significant improvements in production,” said Dr. Kärt Tomberg, CEO & Co-Founder, ExpressionEdits.
  • “Their proprietary intronization technology unlocks the capacity to express highly complex molecules previously deemed unattainable, while regulating them with precision.